Disease · MONDO_0005303

drug dependence

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. drug dependence. Diseases, record MONDO_0005303. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005303

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: drug dependence; Open Targets
Open Targets ID: MONDO_0005303; Open Targets
Other names: Abuse, Drug, Addiction, Drug, DRUG USE DIS, Dependence, Drug, Disorder, Drug Use, Drug Abuse, Drug Addiction, Drug Habituation, Drug Usage, Drug Use Disorder, Drug Use Disorders, Habituation, Drug, Usage, Drug, chemical dependence; Open Targets
Disease Ontology: DOID:9974; Disease Ontology
NCI Thesaurus: C3894; NCI Thesaurus
Highest stage of its drugs: Approval, for 24 of its 30 drugs, from ATC and DailyMed; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUPRENORPHINE	CHEMBL511142	Small molecule	Approval	ATC and DailyMed	7	2	2	Drugs and targets
METHADONE	CHEMBL651	Small molecule	Approval	ATC	2	1	1	Drugs and targets
CODEINE PHOSPHATE	CHEMBL6067642	Small molecule	Approval	DailyMed	6	0	0	Drugs and targets
HYDROCODONE BITARTRATE	CHEMBL3989677	Small molecule	Approval	DailyMed	6	0	0	Drugs and targets
HYDROMORPHONE HYDROCHLORIDE	CHEMBL1237055	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
OXYCODONE	CHEMBL656	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
OXYCODONE HYDROCHLORIDE	CHEMBL1200890	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
BUTORPHANOL TARTRATE	CHEMBL299400	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
METHADONE HYDROCHLORIDE	CHEMBL1200825	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets61

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
OPRM1	Mu-type opioid receptor	16	Mu opioid receptor agonist; Mu opioid receptor partial agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4988	Drugs and targets
OPRK1	Kappa-type opioid receptor	7	Kappa opioid receptor agonist; Kappa opioid receptor partial agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4986	Drugs and targets
OPRD1	Opioid receptors; mu/kappa/delta	4	Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4985	Drugs and targets
SLC6A2	Sodium-dependent noradrenaline transporter	3	Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
SLC18A2	Synaptic vesicular amine transporter	2	Synaptic vesicular amine transporter inhibitor	Approval	https://conductscience.org/library/genes/6571	Drugs and targets
SLC6A3	Sodium-dependent dopamine transporter	2	Dopamine transporter releasing agent	Approval	https://conductscience.org/library/genes/6531	Drugs and targets
ADORA1	Adenosine receptor	1	Adenosine receptor antagonist	Approval	https://conductscience.org/library/genes/134	Drugs and targets
ADORA2A	Adenosine receptor	1	Adenosine receptor antagonist	Approval	https://conductscience.org/library/genes/135	Drugs and targets

1 to 10 of 61

See all 61 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01100853	Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland	Phase 3	100	2014-01-13	Amphetamine Dependence	NALTREXONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02979093	Oxytocin and Brain Responses in Maternal Addiction	Phase 2	59	2025-03-26	Maternal Behavior, Maternal Addiction	OXYTOCIN	Its record names the disease	ClinicalTrials.gov
NCT00420771	Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients	Phase 2	19	2018-07-12	Benzodiazepine Dependence, Opioid Dependence	GABAPENTIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01893632	Gabapentin Treatment of Benzodiazepine Dependence	Phase 2	2	2018-07-24	Benzodiazepine Dependence	GABAPENTIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01560221	Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution	Phase 1	38		Substance-related Disorders, HIV Risk Behavior	BUPRENORPHINE, METHADONE	Its record names the disease	ClinicalTrials.gov
NCT00029614	Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD	Phase 2	24		Substance Use Disorders, Attention Deficit Hyperactivity Disorder	ATOMOXETINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00000205	Buprenorphine Maintenance Protocol - 1	Phase 3	0		Opioid-Related Disorders	BUPRENORPHINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
VIVITROL Injection, 24 Weeks vs VIVITROL Placebo Injection, 24 Weeks: serious adverse events	9 of 51	7 of 49	100	NCT01100853	Trial comparisons
Gabapentin vs Placebo: serious adverse events	0 of 6	0 of 10	16	NCT00420771	Trial comparisons
Gabapentin vs Placebo: Abstinence From Benzodiazepine Use	0 of 1	0 of 1	2	NCT01893632	Trial comparisons
Gabapentin vs Placebo: deaths from any cause	0 of 1	0 of 1	2	NCT01893632	Trial comparisons
Gabapentin vs Placebo: serious adverse events	0 of 1	0 of 1	2	NCT01893632	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
26962719	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005303

GET https://conductscience.org/api/diseases/v1/MONDO_0005303/drugs?page=2

API reference For AI assistants